(Total Views: 401)
Posted On: 11/11/2019 8:40:55 PM
Post# of 154899
" First patient in CytoDyn mTNBC trial shows significant reduction in CTC and reduce tumor size "
" moreover , the reduction of CCR5 expression of EMT cells may prove to be significant as a high CCR5 expression is believed to be crucial for metastasis "
" first treatment of mTNBC with Leronlimab in this phase 1b2 trial in addition to mTNBC patient treated with Leronlimab under emergency IND "
" Results of both of the ongoing trials in MBC will dictate the Company's regulatory pathway , including the potential to seek BTD and accelerated approval.
OK , so results are good in both , and both are presented !!!!!
This is a very big news in medicine ...!!!! very , very big ..!!!!!!
IMO
" moreover , the reduction of CCR5 expression of EMT cells may prove to be significant as a high CCR5 expression is believed to be crucial for metastasis "
" first treatment of mTNBC with Leronlimab in this phase 1b2 trial in addition to mTNBC patient treated with Leronlimab under emergency IND "
" Results of both of the ongoing trials in MBC will dictate the Company's regulatory pathway , including the potential to seek BTD and accelerated approval.
OK , so results are good in both , and both are presented !!!!!
This is a very big news in medicine ...!!!! very , very big ..!!!!!!
IMO
(1)
(0)
